ArticleMalaria journal2021
Systematic identification of plausible pathways to potential harm via problem formulation for investigational releases of a population suppression gene drive to control the human malaria vector Anopheles gambiae in West Africa.
Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- A systematic review assessing the potential for release of vector species from competition following insecticide-based population suppression of Anopheles species in Africa.Parasites & vectors · 2021Pooled it
- Response to "Field Trials Need Genetic Localization, Not Geographic Isolation".The American journal of tropical medicine and hygiene · 2025Article
- Growth and development of two predator species fed a diet of genetically engineered mosquitoes.Parasites & vectors · 2025Article
- Meeting Report on the Symposium "Evolutionary Applications" at the 3rd Joint Congress on Evolutionary Biology.Evolutionary applications · 2025Article
- Integrating malaria vaccine and CRISPR/Cas9 gene drive: a comprehensive strategy for accelerated malaria eradication.Malaria journal · 2025Review
- Cerebral Malaria and Multi-Organ Dysfunction Caused by Plasmodium vivax in an Adult:Sultan Qaboos University medical journal · 2025Review
- Post-release monitoring pathway for the deployment of gene drive-modified mosquitoes for malaria control in Africa.Malaria journal · 2024Article
- Genes drive organisms and slippery slopes.Pathogens and global health · 2024Review
- Considerations for first field trials of low-threshold gene drive for malaria vector control.Malaria journal · 2024Review
- Modelling daisy quorum drive: A short-term bridge across engineered fitness valleys.PLoS genetics · 2024Article
- Taking stock: Is gene drive research delivering on its principles?Gates open research · 2024Article
- Bioinformatic and literature assessment of toxicity and allergenicity of a CRISPR-Cas9 engineered gene drive to control Anopheles gambiae the mosquito vector of human malaria.Malaria journal · 2023Article
- Conceptual risk assessment of mosquito population modification gene-drive systems to control malaria transmission: preliminary hazards list workshops.Frontiers in bioengineering and biotechnology · 2023Article
- Review
- Modeling the efficacy of CRISPR gene drive for snail immunity on schistosomiasis control.PLoS neglected tropical diseases · 2022Article
- Larval mosquito management and risk to aquatic ecosystems: A comparative approach including current tactics and gene-drive Anopheles techniques.Transgenic research · 2022Article
- Population replacement gene drive characteristics for malaria elimination in a range of seasonal transmission settings: a modelling study.Malaria journal · 2022Article
- Lessons learned from the introduction of genetically engineered crops: relevance to gene drive deployment in Africa.Transgenic research · 2022Review
- Recommendations for environmental risk assessment of gene drive applications for malaria vector control.Malaria journal · 2022Article
- Driving down malaria transmission with engineered gene drives.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPopulation suppression gene drive has been proposed as a strategy for malaria vector control. A CRISPR-Cas9-based transgene homing at the doublesex locus (dsxF
methodsBuilding on consultative workshops in Africa that previously identified relevant environmental and health protection goals for ERA of gene drive in malaria vector control, 8 potentially harmful effects from these simulated releases were identified. These were stratified into 46 plausible pathways describing the causal chain of events that would be required for potential harms to occur. Risk hypotheses to interrogate critical steps in each pathway, and an analysis plan involving experiments, modelling and literature review to test each of those risk hypotheses, were developed.
resultsMost potential harms involved increased human (n = 13) or animal (n = 13) disease transmission, emphasizing the importance to subsequent stages of ERA of data on vectorial capacity comparing transgenics to non-transgenics. Although some of the pathways (n = 14) were based on known anatomical alterations in dsxF
conclusionsModelling will play an essential role in subsequent stages of ERA by clarifying the dynamics of this relationship between population suppression and reduction in exposure to specific potential harms. This analysis represents a comprehensive identification of plausible pathways to potential harm using problem formulation for a specific gene drive transgene and organism, and a transparent communication tool that could inform future regulatory studies, guide subsequent stages of ERA, and stimulate further, broader engagement on the use of population suppression gene drive to control malaria vectors in West Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.